The terms of the transaction have not been made public. Credit: Tyler Olson via Shutterstock.

Global clinical trial supply company Myonex has entered into agreement to acquire the clinical, commercial packaging, and bioservices business of Creapharm.  

Creapharm, which is headquartered in Reims, France, operates additional locations in Bordeaux and Bailly-Romainvilliers, France, and in the US city of Marietta. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The strategic move is set to combine Myonex’s drug sourcing and clinical trial prescription services with Creapharm’s clinical packaging and distribution capabilities.  

Specifically, it will enhance Myonex’s capabilities in clinical packaging, labelling, distribution, and supply chain management for advanced therapy medicinal products.

The acquisition is subject to regulatory approval, and the financial terms of the transaction have not been disclosed. 

Myonex CEO James Lovett said: “By combining, we will fill a gap in the market with broad and deep expertise, integrated services, and extraordinary client focus.  

See Also:

“Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upon completion of the transaction, Myonex will retain its current leadership with Mike Cohen as executive chair and Lovett as CEO.  

Meanwhile, Creapharm CEO and founder Eric Placet will reinvest in Myonex and join its board of directors.  

Placet said: “Growing with Myonex is an obvious step for Creapharm to move forward, contributing our expertise and wide range of packaging solutions to their operations while we will expand the range of services we offer in support of always more effective, efficient, patient-centric clinical trials.  

“Creapharm is pleased to evolve the overall mission of Myonex through our complementary strengths and to provide scale and flexibility in meeting our clients’ needs.”